Annals of Nuclear Medicine

, Volume 8, Issue 2, pp 115–123 | Cite as

Intra-arterial infusion of N-isopropyl-p[123I]iodoamphetamine for assessing effective blood supply to pulmonary and hepatic neoplasms

  • Chihoko Miyazaki
Original Article


The biodistribution and pharmacokinetics of intra-arterially administered N-isopropyl-p[123I] iodoamphetamine (123I-IMP) were prospectively evaluated in 38 patients with histologically proven pulmonary or hepatic tumors. Intra-arterially infused123I-IMP was distributed initially in peripheral tissues in which the blood supply was maintained. Its concentration in malignant neoplasms was demonstrated to be higher than in normal tissues. In pulmonary cancer, the tumor uptake of the administered dose without a tissue attenuation correction (% uptake) of123I-IMP at 1–2 min after injection was 14.7 ± 5.7% (s.d.). The tumor to normal tissue ratio was 2.1 ± 0.7 in hepatocellular carcinoma and 1.4 ± 0.7 in metastatic tumors. The biodistribution of123I-IMP was also compared to that of99mTc-macroaggregated albumin (99mTc-MAA) in 9 cases of hepatic cancer. The distribution of123I-IMP resembled that of99mTc-MAA in 5 cases and was different in 4 cases.123I-IMP was more concentrated in the tumor than99mTc-MAA.

Intra-arterial infusion scintigraphy with123I-IMP seems to provide information on effective blood supply to neoplasms which are targeted in interventional radiology.

Key words

tumor blood flow intra-arterial infusion N-isopropyl-p[123I]iodoamphetamine (123I-IMP) interventional radiology 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Diksic M, Sako K, Feindel W, Kato A, Yamamoto YL, Farrokhzad S, et al. Pharmacokinetics of positron-labeled 1,3-Bis(2-chloroethyl)nitrosourea in human brain tumors using positron emission tomography.Cancer Res 44: 3120–3124, 1984.PubMedGoogle Scholar
  2. 2.
    Tyler JL, Yarnamoto YL, Diksic M, Theron J, Villemure JG, Worthington C, et al. Pharmacokinetics of superselective intra-arterialandintravenous[11C]BCNU evaluated by PET.J Nucl Med 27: 775–780, 1986.PubMedGoogle Scholar
  3. 3.
    Ginos JZ, Cooper AL, Dhawan V, Lai JCK, Strother SC, Alcock N, et al. [13N]Cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors.J Nucl Med 28: 1844–1852, 1987.PubMedGoogle Scholar
  4. 4.
    Kim EE, Haynie T. Role of nuclear medicine in chemotherapy of malignant lesions.Semin Nucl Med 15: 12–20, 1985.PubMedCrossRefGoogle Scholar
  5. 5.
    Yang PJ, Thrall JH, Ensminger WD, Niederhuber JE, Gyves JW, Tuscan M, et al. Perfusion Scintigraphy (Tc-99m MAA) during surgery for placement of chemotherapy catheter in hepatic artery: concise communication.J Nucl Med 23: 1066–1069, 1982.PubMedGoogle Scholar
  6. 6.
    Bledin AG, Kantarjian HM, Kim EE, Wallace S, Chuang VP, Patt YZ, et al.99mTc-labeled macroaggregated albumin in intrahepatic arterial chemotherapy.Am J Roentgenol 139: 711–715, 1982.Google Scholar
  7. 7.
    Rodari A, Bonfanti G, Garbagnati F, Marolda R, Milella M, Buraggi GL. Microsphere angiography in hapatic artery infusion for cancer.EurJ Nucl Med 6: 473–476, 1981.Google Scholar
  8. 8.
    Sasaki Y, Imaoka S, Hasegawa Y, Nakano S, Ishikawa O, Ohigashi H, et al. Distribution of arterial blood flow in human hepatic cancer during chemotherapy-examination by short-lived81mKr.Surgery 97: 409–413, 1985.PubMedGoogle Scholar
  9. 9.
    Sigurdson ER, Ridge JA, Daly JM. Fluorodeoxyuridine uptake by human colorectal hepatic metastases after hepatic artery infusion.Surgery 100: 285–291, 1986.PubMedGoogle Scholar
  10. 10.
    Ridge JA, Sigurdson ER, Daly JM. Distribution of fluorodeoxyuridine uptake in the liver and colorectal hepatic metastases of human beings after arterial infusion.Surg Gynecol Obstet 164: 319–323, 1987.PubMedGoogle Scholar
  11. 11.
    Sigurdson ER, Ridge JA, Kemeny N, Daly JM. Tumor and liver drug uptake following hepatic artery and portal vein infusion.J Clin Oncol 5: 1836–1840, 1987.PubMedGoogle Scholar
  12. 12.
    Kaplan WD, Ensminger WD, Come SE, Smith EH, D’Orsi CJ, Levin DC, et al. Radionuclide angiography to predict patient response to hepatic artery chemotherapy.Cancer Treat Rep 64: 1217–1222, 1980.PubMedGoogle Scholar
  13. 13.
    Daly JM, Butler J, Kemeny N, Yeh SDJ, Ridge JA, Botet J, et al. Predicting tumor response in patients with colorectal hepatic metastases.Ann Surg 202: 384–393, 1985.PubMedCrossRefGoogle Scholar
  14. 14.
    Lassen NA, Henriksen L, Holm S, Barry DL, Paulson OB, Vorstrup S, et al. Cerebral blood flow tomography: Xenon-133 compared with isopropylamphetamine Iodine 123 concise communication.J Nucl Med 24: 17–21, 1983.PubMedGoogle Scholar
  15. 15.
    Drayer B, Jaszczak R, Friedman A, Albright R, Kung H, Greer K, et al.In vivo quantitation of regional cerebral blood flow in glioma and cerebral infarction: validation of the HIPDm-SPECT method.AJNR 4: 572–576, 1983.PubMedGoogle Scholar
  16. 16.
    Winchell HS, Baldwin RM, Lin TH. Development of I-123-labeled amines for brain studies: Localization of I-123 iodophenylalkyl amines in rat brain.J Nucl Med 21: 940–946, 1980.PubMedGoogle Scholar
  17. 17.
    Winchell HS, Horst WD, Braun L, Oldendorf WH, Hattner R, Parker H, et al. N-isopropyl-[123I]p-iodoamphetamine: Single-pass brain uptake and washout; Binding to brain synaptosomes; and localization in dog and monkey brain.J Nucl Med 21: 947–952, 1980.PubMedGoogle Scholar
  18. 18.
    Kuhl DE, Barrio JR, Huang SC, Selin C, Ackermann RF, Lear JJ, et al. Quantifying local cerebral blood flow by N-isopropyl-p-[123I]iodoamphetamine (IMP) tomography.J Nucl Med 23: 196–203, 1982.PubMedGoogle Scholar
  19. 19.
    Holman BL, Lee RGL, Hill TC, Lovett RD, Lister-James J. A comparison of two cerebral perfusion tracers, N-isopropyl I-123 p-iodoamphetamine and I-123 HIPDM, in the human.J Nucl Med 25: 25–30, 1984.PubMedGoogle Scholar
  20. 20.
    Moretti JL, Cinotti L, Cesaro P, Defer G, Joulin Y, Sergent A, et al. Amines for brain tomoscintigraphy.Nucl Med Commun 8: 581–595, 1987.PubMedGoogle Scholar
  21. 21.
    Stagg RJ, Lewis BJ, Friedman MA, Ignoffo RJ, Hohn DC. Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver.Ann Intern Med 100: 736–743, 1984.PubMedGoogle Scholar
  22. 22.
    Andrews JC, Williams DM, Cho KJ, Knol JA, Wahl RL, Ensminger WD. Unsatisfactory hepatic perfusion after placement of an implanted pump and catheter system: angiographic correlation.Radiology 173: 779–781, 1989.PubMedGoogle Scholar
  23. 23.
    Cho KJ, Andrews JC, Williams DM, Doenz F, Guy GE. Hepatic arterial chemotherapy: role of angiography.Radiology 173: 783–791, 1989.PubMedGoogle Scholar
  24. 24.
    Charnsangavej C, Carrasco CH, Wallace S, Richli W, Haynie TP. Hepatic arterial flow distribution with hepatic neoplasms: significance in infusion chemotherapy.Radiology 165: 71–73, 1987.PubMedGoogle Scholar
  25. 25.
    Lutz RJ, Miller DL. Mixing studies during hepatic arterial infusion in anin vitro model.Cancer 62: 1066–1073, 1988.PubMedCrossRefGoogle Scholar
  26. 26.
    Bookstein JJ, Cho KJ, Davis GB, Dail D. Arterioportal communications: observations and hypotheses concerning transsinusoidal and transvasai types.Radiology 142: 581–590, 1982.PubMedGoogle Scholar
  27. 27.
    Fishman AP, Fisher AB, Geiger SR. The respiratory system.Handbook of Physiology. Vol. 1. Sec. 3. Bethesda: American physiological society, 1985.Google Scholar
  28. 28.
    Nakajo M, Kobayashi H, Shimabukuro K, Shirono K, Sakata H, Taguchi M, et al. Biodistribution andin vivo kinetics of iodine-131 lipiodol infused via the hepatic artery of patients with hepatic cancer.J Nucl Med 29: 1066–1077, 1988.PubMedGoogle Scholar
  29. 29.
    Raoul JL, Bourguet P, Bretagne JF, Duvauferrier R, Coornaert S, Darnault P, et al. Hepatic artery injection of I-131-labeled lipiodol.Radiology 168: 541–545, 1988.PubMedGoogle Scholar
  30. 30.
    Gyves JW, Ziessman HA, Ensminger WD, Thrall JH, Niederhuber JE, Keyes JW. Definition of hepatic tumor microcirculation by single photon emission computerized tomography (SPECT).J Nucl Med 25: 972–977, 1984.PubMedGoogle Scholar
  31. 31.
    Rahimian J, Glass EC, Touya JJ, Akber SF, Graham LS, Bennett LR. Measurement of metabolic extraction of tracers in the lung using a multiple indicator dilution technique.J Nucl Med 25: 31–37, 1984.PubMedGoogle Scholar
  32. 32.
    Touya JJ, Rahimian J, Corbus HF, Grubbs DE, Savala KM, Glass EC, et al. The lung as a metabolic organ.Semin Nucl Med 16: 296–305, 1986.PubMedCrossRefGoogle Scholar
  33. 33.
    Nakajo M, Shimada J, Shimozono M, Uchiyama N, Hiraki Y, Shinohara S. Serial lung imaging with123I-DVIP in localized pulmonary lesions.KAKU IGAKU (Jpn J Nucl Med) 25: 441–450, 1988.Google Scholar
  34. 34.
    Suga K, Matsumoto T, Nakanishi T, Yokoyama T, Tanaka K, Nakamura H, et al. Clinical study on the mechanism of abnormal accumulation in lung scanning with N-isopropyl-p-123I-iodoamphetamme (123I-IMP).KAKU IGAKU (Jpn J Nucl Med) 25: 625–631, 1988.Google Scholar
  35. 35.
    Kosuda S, Kawahara S, Tamura K, Ishikawa N, Ono A, Kubo A, et al. N-isopropyl-p-[I-123]iodoamphetamine lung imaging in a patient with chronic pulmonary thromboembolism.Clin Nucl Med 14: 756–758, 1989.PubMedCrossRefGoogle Scholar
  36. 36.
    Herba MJ, Illescas FF, Thirlwell MP, Boos GJ, Rosenthall L, Atri M, et al. Hepatic malignancies: improved treatment with intraarterial Y-90.Radiology 169: 311–314, 1988.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • Chihoko Miyazaki
    • 1
  1. 1.Department of Diagnostic RadiologySapporo City General HospitalSapporoJapan

Personalised recommendations